GenScript CytoSinct™ Nanobeads Products and Services 제품을 소개합니다.

GenScript CytoSinct™ Nanobeads는 수십 년간 축적된 항체 개발 및 magnetic bead 생산 전문 기술을 활용하여 특정 세포 집단을 정밀하게 분리합니다. 이 Nanobeads는 biodegradable matrix로 구성된 superparamagnetic nanoparticles로, 고도로 특이적인 단일클론 항체가 미리 접합되어 있습니다. 탈비드 과정 없이 간편하게 사용할 수 있으며, 말초혈액 단핵세포(PBMC) 및 백혈구 팩을 포함한 다양한 원료로부터 매우 효율적인 세포 분리를 제공합니다. 분리된 표적 세포는 생존력이 매우 높아 세포 배양, 활성화, 증식, 유세포 분석, 유전자 편집, 동물 모델 이식 등 다양한 후속 응용 분야에 활용될 수 있습니다. 연구용 (RUO) 및 GMP 등급으로 제공되며, 다양한 표적에 적용 가능합니다. 연구용으로는 CytoSinct™ Manual Separator와, 제조용으로는 CytoSinct™ 1000 자동화 장비와 함께 사용할 수 있습니다.

CytoSinct™ Nanobeads는 널리 사용되는 표적에 맞춰 바로 사용할 수 있는 형태로 제공되거나, 고객 사양에 따라 완벽하게 맞춤 제작할 수 있습니다.

[Workflow]

GenScript's CytoSinct™ Nanobeads는 컬럼 기반 분리 방법을 사용하여 세포를 정제합니다. 

* 이 Nanobeads는 GenScript 또는 다른 공급업체의 세포 분리용 자기 컬럼과 호환됩니다.

[Applications]

T cell Isolation with high purity, recovery and viability from PBMC

The combined enrichment of CD4+ and CD8+ T lymphocytes is a common cell isolation strategy to produce T cell-based therapies like CAR T. GenScript provides both CytoSinct™ CD4 and CD8 nanobeads. The two magnetic beads can be incubated with the staring material like PBMC or leukopak at the same time and processed for T cell isolation in one-step and obtain high-purity and high-recovery target cells without impact on cell viability.

Figure 1: PBMCs from different donors were treated with CytoSinct™ or competitor CD4 and CD8 magnetic beads and CytoSinct™ manual separator followed by flow cytometry analysis. (A) Representative result of post-isolation using CytoSinct™ products in comparison to the current standard technology. (B) Cell viability before and after isolation using CytoSinct™ Nanobeads, (C) Purity of T-cells after isolation using CytoSinct™ Nanobeads. (D) Recovery of CD4+ and CD8+ T cell after isolation using CytoSinct™ Nanobeads.

Single-Step αβ T Cell Depletion with CytoSinct™ TCRαβ Nanobeads

GenScript’s CytoSinct™ TCRαβ Nanobeads feature an innovative one-step protocol that simplifies workflows and overcomes the challenges of traditional methods—such as lengthy procedures, complexity, and high cell loss. Designed for use with allogeneic CAR-T, γδ T, and CAR-NK cell therapy development, this technology efficiently removes αβ T cells while maximizing the recovery of desired cell populations.

Figure 2: TCRαβ depletion using CytoSinct™ TCRαβ nanobeads for allogeneic CAR-T and γδ T cell production from various healthy donor PBMC samples and analyzed by flow cytometry. (A) CD3+ cell percentage after TCRαβ depletion maintained below 0.1%; (B) Purity and recovery of target cell population (allogeneic CAR-T or γδ T) in final products. 

Figure 3: TCRαβ depletion using CytoSinct™ TCRαβ nanobeads for CAR-NK cell production from various healthy donor PBMC samples and analyzed by flow cytometry. (A) CD3+ cell percentage after TCRαβ depletion; (B) CD3-CD56+NK cell purity and recovery after TCRαβ depletion.

Highly Efficient NK Cell Isolation

NK cells are usually enriched from PBMC or leukopaks by CD3+ cell removal followed by CD56+ cell enrichment for NK cell or CAR-NK cell therapy production. GenScript CytoSinct™ provides both CD3 and CD56 Nanobeads for highly efficient NK cell enrichment.

Figure 4. NK cell enrichment from various PBMC samples via CD3+ cell depletion followed by CD56+ cell enrichment using CytoSinct™ CD3 and CD56 Nanobeads or the current standard method. Percentage of T cells (A), NKT cells (B), and NK cells (C) before or after isolation were analyzed by flow cytometry, and the NK cell recovery rate of the whole process (D) and the NK cell recovery rate in CD56 enrichment (E) were evaluated.

CD34+ Cell Enrichment With Enhanced Safety

CD34 is validated biomarker of human hematopoietic stem and progenitor cells (HSC and HPC). CD34+ cells are widely used in bone marrow transplant and gene-edited stem cell therapies. To ensure its safety, the Fc region of the CD34 antibody used in CytoSinct™ CD34 Nanobeads was humanized to reduce heterology and reduce the risk of producing human anti-mouse antibodies (HAMA). It is also and optimized to reduce non-specific binding of Fc region.

Figure 5. CD34+ cells were enriched from the starting material using CytoSinct™ CD34 Nanobeads or the current standard method followed by flow cytometry analysis. High purity and recovery of CD34+ cells were achieved after isolation and highly comparable as using the current standard method. 

B Cell Isolation

Figure 6.Enrichment or depletion of CD19+ B cells from PBMC samples using CytoSinct™ CD19 Nanobeads followed by flow cytometry analysis. (A) Representative histogram of CD19+ and CD19- cells before isolation; (B-C) Percentage of CD19+ cells in the positive portion and negative portion after isolation.

[Selection Guide]